PACB News and Press, Pacific Biosciences of California Inc. From 02/06/23

Summary The gene sequencing market is ripe for disruption. ILMN suffers from multiple strategic setbacks that will likely impact margins for years. Oxford Nanopore and Pacific Biosciences will likely grow at a faster pace than ILMN. The industry trades at high price multiples. ...

PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023 PR Newswire MENLO PARK, Calif. , Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth qua...

Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

PacBio ( NASDAQ: PACB ) has priced an upsized public offering of common stock expected to bring in $175M at $10 per share. The offering is for 17.5M shares. Underwriters have a 30-day option to purchase and additional 2.625M shares. The offering was originally for $150M wort...

Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock PR Newswire MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it has ...

Pacific Biosciences of California ( NASDAQ: PACB ) said it expects to offer and sell $150M shares in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5M shares at the public offering price, less unde...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Bruker offers a range of advantages over peers: profitability, value, growth, and more. As such, the company is well-positioned to provide strong returns in the future. This article will address recent developments, highlight the advantages, and discuss the opportunity. ...

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year" PR Newswire MENLO PARK, Calif. , Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrate...